Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta‐analysis

Documenti analoghi

• Personalized, tumor‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments
  di: Youjin Oh, et al.
  Pubblicazione: (2024)
• Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer
  di: Aaron C. Tan, et al.
  Pubblicazione: (2024)
• Determining risk‐adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors
  di: Tung Hoang, et al.
  Pubblicazione: (2024)
• Advancing molecular residual disease detection in cervical cancer through next‐generation sequencing of circulating human papillomavirus DNA
  di: Kathy Han
  Pubblicazione: (2026)
• Blood‐based cell‐free DNA and multitarget stool RNA screening tests to detect colorectal cancer: A systematic review
  di: Karli K. Kondo, et al.
  Pubblicazione: (2026)